In Brief: First Medical, Inc.
This article was originally published in The Gray Sheet
Executive Summary
First Medical, Inc.: Walter Narajowski is named president and CEO. Narajowski formerly served as VP and general manager of the Abbott Hospital Product Division's infusion pumps and critical care products businesses. Former President and CEO David McCaslin left last summer by mutual agreement with the board, the company explains. First Medical also announces the submission in December of a 510(k) submission to FDA for its Alpha Dx clinical decision support system. The device uses whole blood "for the rapid, quantitative and simultaneous measurement of a panel of tests," including myoglobin, CK, CK-MB, relative index and troponin I, "to aid in the diagnosis of acute myocardial infarction"...
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.